New drugs in preclinical and early stage clinical development in the treatment of heart failure

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. AHASC. Stroke Statistics Subcommittee. Circulation. 2016;133:e38–e60.
   PubMed Web of Science ®Google Scholar
• Metra M, Teerlink JR. Heart failure. Lancet. 2017;390:1891–1895.
   Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force M, document R.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–1852.
   PubMed Web of Science ®Google Scholar
• van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18:242–252.
   PubMed Web of Science ®Google Scholar
• Butler J, Gheorghiade M, Kelkar A, et al. In-hospital worsening heart failure. Eur J Heart Fail. 2015;17:1104–1113.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Senni M, Metra M, et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013;6:473–481.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544–558.
   PubMed Web of Science ®Google Scholar
• Collins S, Storrow AB, Albert NM, et al. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the Society for Academic Emergency Medicine/Heart Failure Society of America acute Heart Failure Working Group. J Card Fail. 2015;21:27–43.
   PubMed Web of Science ®Google Scholar
• Tamargo J, López-Sendón JL. Novel therapeutic targets for the treatment of heart failure. Nat Drug Discovery Rev. 2011;10:536–555.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Rosano GM, Delpón E, et al. Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. Int J Cardiol. 2017;233:1–11.
   PubMed Web of Science ®Google Scholar
• Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014;2:97–112.
   PubMed Web of Science ®Google Scholar
• Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction. Circulation. 2016;134:73–90.
   PubMed Web of Science ®Google Scholar
• Senni M, Greene SJ, Butler J, et al. Drug development for heart failure with preserved ejection fraction: what pieces are missing from the puzzle? Can J Cardiol. 2017;33:768–776.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178–1186.
   PubMed Web of Science ®Google Scholar
• Hartog JW, Willemsen S, van Veldhuisen DJ, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13:899–900.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227–1234.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016;374:1521–1532.
   PubMed Web of Science ®Google Scholar
• Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) Study. Circulation. 2015;131:1763–1771.
   PubMed Web of Science ®Google Scholar
• Abraham W. Phase II trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure: GENETIC-AF. Heart Failure 2018 & World Congress on Acute Heart Failure; Viena; 2018. p. 674 (Abstract).
   Google Scholar
• McMurray JJ, Anand IS, Diaz R, et al. Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). Eur J Heart Fail. 2013;15:334–341.
   PubMed Web of Science ®Google Scholar
• Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347–353.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200–1210.
   PubMed Web of Science ®Google Scholar
• Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51(pii:1701886).
   Google Scholar
• Wong AK, Symon R, AlZadjali MA, et al. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail. 2012;14:1303–1310.
   PubMed Web of Science ®Google Scholar
• Bundgaard H, Axelsson A, Thomsen J, et al. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail. 2017;19:566–575.
   PubMed Web of Science ®Google Scholar
• Bonderman D, Ghio S, Felix SB, et al. Left ventricular systolic dysfunction associated with Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502–511.
   PubMed Web of Science ®Google Scholar
• Fernandes AM, Andrade AC, Barroso ND, et al. The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial. PLoS One. 2015;10:e0119623.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314:2251–2262.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Böhm M, Cleland JGF, et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail. 2015;17:665–671.
   PubMed Web of Science ®Google Scholar
• Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail. 2015;8:1052–1058.
   PubMed Web of Science ®Google Scholar
• Lund LH, Benson L, Dahlström U, et al. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312:2008–2018.
   PubMed Web of Science ®Google Scholar
• Patel K, Fonarow GC, Ekundayo OJ, et al. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. Int J Cardiol. 2014;173:393–401.
   PubMed Web of Science ®Google Scholar
• Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial). Heart Lung Circ. 2017;26:433–441.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15:110–118.
   PubMed Web of Science ®Google Scholar
• Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010;3:477–485.
   PubMed Web of Science ®Google Scholar
• Deswal A, Richardson P, Bozkurt B, et al. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17:634–642.
   PubMed Web of Science ®Google Scholar
• Zamani P, Tan V, Soto-Calderon H, et al. Pharmacokinetics and pharmacodynamics of inorganic nitrate in heart failure with preserved ejection fraction. Circ Res. 2017;120:1151–1161.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Anstrom KJ, Levine JA, et al. NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373:2314–2324.
   PubMed Web of Science ®Google Scholar
• Zamani P, Akers S, Soto-Calderon H, et al. Isosorbide dinitrate, with or without hydralazine, does not reduce wave reflections, left ventricular hypertrophy, or myocardial fibrosis in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2017;6:pii: e004262.
   PubMed Web of Science ®Google Scholar
• Pal N, Sivaswamy N, Mahmod M, et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015;132:1719–1725.
   PubMed Web of Science ®Google Scholar
• Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495–1503.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
   PubMed Web of Science ®Google Scholar
• Lim SL, Benson L, Dahlstrom U, et al. Association between use of long-acting nitrates and outcomes in heart failure with preserved ejection fraction. Circ Heart Fail. 2017;10:e003534.
   PubMed Web of Science ®Google Scholar
• Kaye DM, Nanayakkara S, Vizi D, et al. Effects of milrinone on rest and exercise hemodynamics in heart failure with preserved ejection fraction. Jacc. 2016;67:2554–2556.
   Google Scholar
• Borlaug BA, Anstrom K, Lewis G, et al. Inorganic nitrite delivery to improve exercise capacity in heart failure with preserved ejection fraction: the INDIE trial. Late-breaking clinical trial III. American College of Cardiology Scientific Session; 2018 Mar 10-12; Orlando, Fla. Presentation 405-10.
   Google Scholar
• Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219–225.
   PubMed Web of Science ®Google Scholar
• Maier LS, Layug B, Karwatowska E. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013;1:115–122.
   PubMed Web of Science ®Google Scholar
• Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146:1274–1285.
   PubMed Web of Science ®Google Scholar
• Redfield M, Chen HH, Borlaug BA, et al. RELAX trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–1277.
   PubMed Web of Science ®Google Scholar
• Hussain I, Mohammed SF, Forfia PR, et al. Impaired right ventricular–pulmonary arterial coupling and effect of sildenafil in heart failure with preserved ejection fraction: an ancillary analysis from the phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial. Circ Heart Fail. 2016;9:e002729.
   PubMed Web of Science ®Google Scholar
• Andersen MJ, Ersbøll M, Axelsson A, et al. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation. 2013;127:1200–1208.
   PubMed Web of Science ®Google Scholar
• Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36:2565–2573.
   PubMed Web of Science ®Google Scholar
• Borlaug BA, Melenovsky V, Koepp KE. Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction. Circ Res. 2016;119:880–886.
   PubMed Web of Science ®Google Scholar
• Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2015;66:1672–1682.
   PubMed Web of Science ®Google Scholar
• Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–791.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
   PubMed Web of Science ®Google Scholar
• Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38:1119–1127.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Michel A, Hall K, et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail. 2016;18:54–65.
   PubMed Web of Science ®Google Scholar
• Martens P, Mullens W. How to tackle congestion in acute heart failure. Korean J Intern Med. 2018;33:462–473.
   PubMed Web of Science ®Google Scholar
• Singh A, Laribi S, Teerlink JR, et al. Agents with vasodilator properties in acute heart failure. Eur Heart J. 2017;38:317–325.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on post-discharge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial. JAMA. 2013;309:1125–1135.
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Canada J, Carbone S, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently decompensated heart failure anakinra response trial). Circ Heart Fail. 2017;10:pii: e004373.
   PubMed Web of Science ®Google Scholar
• Matsue Y, Kagiyama N, Yoshida K, et al. Carperitide is associated with increased in-hospital mortality in acute heart failure: a propensity score-matched analysis. J Card Fail. 2015;21:859–864.
   PubMed Web of Science ®Google Scholar
• Ogiso M, Isogai T, Okabe Y, et al. Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses. Heart Vessels. 2017;32:916–925.
   PubMed Web of Science ®Google Scholar
• Mizuno A, Iguchi H, Sawada Y, et al. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: high value care vs. low value care campaign in Japan. Int J Cardiol. 2017;241:243–248.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14:1056–1066.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Semigran MJ, Nieminen MS, et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013;34:57–67.
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
   PubMed Web of Science ®Google Scholar
• Chen HH, Anstrom KJ, Givertz MM, et al. NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310:2533–2543.
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci WS, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103–111.
   PubMed Web of Science ®Google Scholar
• Margulies KB, Hernandez AF, Redfield M, et al. NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction a randomized clinical trial. JAMA. 2016;316:500–508.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Glaser R, Cavender MA, et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA. 2016;315:1591–1599.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Eng J Med. 2011;365:32–43.
   PubMed Web of Science ®Google Scholar
• Herrero-Puente P, Jacob J, Martín-Sánchez FJ, et al. Influence of intravenous nitrate treatment on early mortality among patients with acute heart failure. NITRO-EAHFE study. Rev Esp Cardiol. 2015;68:959–967.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Felker GM, McMurray JJ, et al. ATOMIC-AHF investigators acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016;67:1444–1455.
   PubMed Web of Science ®Google Scholar
• Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419–1428.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Voors AA, Ponikowski P, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the relax-ahf-2 study. Eur J Heart Fail. 2017;19:800-809.
   PubMed Web of Science ®Google Scholar
• Butler J, Anstrom KJ, Felker GM, et al. National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2:950–958.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:1399–1406.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Kiernan M, Chandler A, et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69:1409–1419.
   PubMed Web of Science ®Google Scholar
• Pang PS, Butler J, Collins SP, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017;38:2364–2373.
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956–1964.
   PubMed Web of Science ®Google Scholar
• Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12–19.
   PubMed Web of Science ®Google Scholar
• Gilotra NA, Princewill O, Marino B, et al. Efficacy of intravenous furosemide versus a novel, ph-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6:65–70.
   PubMed Web of Science ®Google Scholar
• Purschke WG, Eulberg D, Buchner K, et al. An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc Natl Acad Sci U S A. 2006;103:5173–5178.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Gómez R, et al. Investigational positive inotropic agents for acute heart failure. Cardiovasc Haematol Disord-Drug Target. 2009;9:193–205.
   PubMedGoogle Scholar
• Tamargo J, Amorós I, Barana A, et al. New investigational drugs for the management of acute heart failure syndromes. Curr Med Chem. 2010;17:363–390.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276–2285.
   PubMed Web of Science ®Google Scholar
• Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439–1443.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Felker GM, McMurray JJ, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388:2895–2903.
   PubMed Web of Science ®Google Scholar
• Aronson D, Krum H. Novel therapies in acute and chronic heart failure. Pharmacol Ther. 2012;135:1–17.
   PubMed Web of Science ®Google Scholar
• Kadota S, Carey J, Reinecke H, et al. Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure. Eur J Heart Fail. 2015;17:772–781.
   PubMed Web of Science ®Google Scholar
• Teichman SL, Kadota S, Regnier M, et al. BB-R12, A novel gene therapy for heart failure. Circulation. 2014;130:A15856.
   Google Scholar
• Japp AG, Cruden NL, Barnes G, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121:1818–1827.
   PubMed Web of Science ®Google Scholar
• Barnes GD, Alam S, Carter G, et al. Sustained cardiovascular actions of APJ agonism during renin–angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6:482–491.
   PubMed Web of Science ®Google Scholar
• Lund LH, Benson L, Dahlstrom U, et al. Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108–2117.
   PubMed Web of Science ®Google Scholar
• Khan MS, Fonarow GC, Khan H, et al. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2017;4:402–408.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Connolly SJ, Abraham WT, et al. A genotype-directed comparative effectiveness trial of bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: rationale and design of the GENETIC-AF trial. Am Heart J. 2018;199:51–58.
   PubMed Web of Science ®Google Scholar
• Balligand JL. Cardiac salvage by tweaking with beta-3-adrenergic receptors. Cardiovasc Res. 2016;111:128–133.
   PubMed Web of Science ®Google Scholar
• Cannavaro A, Koch WJ. Targeting β3-adrenergic receptors in the heart: selective agonism and β-blockade. J Cardiovasc Pharmacol. 2017;69:71–78.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.
   PubMed Web of Science ®Google Scholar
• Asakura M, Yamamoto H, Asai K, et al. Rationale and design of the double-blind, randomized, placebo-controlled multicenter trial on efficacy of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER). Cardiovasc Drugs Ther. 2015;29:179–185.
   PubMed Web of Science ®Google Scholar
• Tamargo M, Tamargo J. Future drug discovery in renin-angiotensin-aldosterone system intervention. Expert Opin Drug Discov. 2017;12:827–848.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37:2105–2114.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Rizkala AR, Lefkowitz MP, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ Heart Fail. 2018;11:e004962.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Gupta RC, Tinel H. Long-term therapy with a chymase-1 inhibitor (BAY 1142524) improves left ventricular systolic function and prevents progressive chamber remodeling in dogs with heart failure. Circulation. 2017;136:A11585.
   Web of Science ®Google Scholar
• Mebazaa A, Longrois D, Metra M, et al. Agents with vasodilator properties in acute heart failure: how to design successful trials. Eur J Heart Fail. 2015;17:652–664.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Butler J, Pitt B, et al. Contemporary drug development in heart failure: call for hemodynamically neutral therapies. Circ Heart Fail. 2015;8:826–831.
   PubMed Web of Science ®Google Scholar
• McNamara DM, Taylor AL, Tam SW, et al. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. JACC Heart Fail. 2014;2:551–557.
   PubMed Web of Science ®Google Scholar
• Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;8:CD005151.
   PubMedGoogle Scholar
• Simon MA, Vanderpool RR, Nouraie M, et al. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight. 2016;1:e89620.
   PubMed Web of Science ®Google Scholar
• Ormerod JPO, Arid S, Mudakam M, et al. Short-term intravenous sodium nitrite infusion improves cardiac and pulmonary hemodynamics in heart failure patients. Circ Heart Fail. 2015;8:565–571.
   PubMed Web of Science ®Google Scholar
• Galié N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.
   PubMed Web of Science ®Google Scholar
• Lee DI, Zhu G, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015;519:472–476.
   PubMed Web of Science ®Google Scholar
• Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263–2273.
   PubMed Web of Science ®Google Scholar
• Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–425.
   PubMed Web of Science ®Google Scholar
• Arcaro A, Lembo G, Tocchetti CG. Nitroxyl (HNO) for treatment of acute heart failure. Curr Heart Fail Rep. 2014;11:227–235.
   PubMedGoogle Scholar
• Kemp-Harper BK, Horowitz JD, Ritchie RH. Therapeutic potential of nitroxyl (HNO) donors in the management of acute decompensated heart failure. Drugs. 2016;76:1337–1348.
   PubMed Web of Science ®Google Scholar
• Tita C, Gilbert E, Van Bakel AB, et al. A phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19:1321–1332.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen C, Feng C, et al. AVE 3085, a novel endothelial nitric oxide synthase enhancer, attenuates cardiac remodeling in mice through the smad signaling pathway. Arch Biochem Biophys. 2015;570:8–13.
   PubMed Web of Science ®Google Scholar
• Galindo CL, Ryzhov S, Sawyer DB. Neuregulin as a heart failure therapy and mediator of reverse remodeling. Curr Heart Fail Rep. 2014;11:40–49.
   PubMedGoogle Scholar
• Yin H-J, Li X-Y, Jiang Z-G, et al. Progress in neuregulin/ErbB signaling and chronic heart failure. World J Hypertens. 2015;5:63–73.
   Google Scholar
• Gao R, Zhang J, Cheng L, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55:1907–1914.
   PubMed Web of Science ®Google Scholar
• Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13:83–92.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Anderson S, Geisberg C, et al. Safety and tolerability of glial growth factor 2 in patients with chronic heart failure: a phase I single dose escalation study. J Am College Cardiol. 2013;61:E707.
   Google Scholar
• Du XJ, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48–58.
   PubMed Web of Science ®Google Scholar
• Díez J, Ruilope LM. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. Eur Heart J-Cardiovasc Pharmacother. 2016;2:119–130.
   PubMed Web of Science ®Google Scholar
• Devarakonda T, Salloum FN. Heart disease and relaxin: new actions for an old hormone. Trends Endocrinol Metab. 2018;29:338–348.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429–1439.
   PubMed Web of Science ®Google Scholar
• Stirrat CG, Venkatasubramanian S, Pawade T, et al. Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. Br J Clin Pharmacol. 2016;82:974–982.
   PubMed Web of Science ®Google Scholar
• Charles CJ, Jardine DL, Rademaker MT, et al. Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep. J Endocrinol. 2010;204:181–189.
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Richards AM. Urocortins: actions in health and heart failure. Clin Chim Acta. 2017;474:76–87.
   PubMed Web of Science ®Google Scholar
• Chan WY, Frampton CM, Crozier IG, et al. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Fail. 2013;1:433–441.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Ponikowski P, et al. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. Eur J Heart Fail. 2013;15:679–689.
   PubMed Web of Science ®Google Scholar
• Grossman NL, Fiack CA, Weinberg JM, et al. Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost. Pulm Circ. 2015;5:198–203.
   PubMed Web of Science ®Google Scholar
• Andersen MJ, Hwang SJ, Kane GC, et al. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail. 2015;8:542–550.
   PubMed Web of Science ®Google Scholar
• Ward CL, Jamieson V, Nabata T, et al. First clinical experience with ONO-4232: a randomized, double-blind, placebo-controlled healthy volunteer study of a novel lusitropic agent for acutely decompensated heart failure. Clin Ther. 2016;38:1109–1121.
   PubMed Web of Science ®Google Scholar
• PB1046: A long-acting VIP analogue. [cited 2018 May 15]. Available from: https://phasebio.com/pipeline/pb1046/.
   Google Scholar
• Thorneloe KS, Cheung M, Bao W, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4:159ra148.
   PubMed Web of Science ®Google Scholar
• Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008;153:1128–1132.
   PubMed Web of Science ®Google Scholar
• Murray GL, Colombo J. Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure. Heart Int. 2014;9:66–73.
   PubMedGoogle Scholar
• Zamani P, Barnard D, Contasti A, et al. Ranolazine increases exercise capacity in heart failure with preserved ejection fraction (HFpEF). J Cardiac Fail. 2015;21(Suppl):S106.
   Google Scholar
• Kosmala W, Holland DJ, Rojek A, et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–1338.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Larson CJ, Shah SJ, et al. Developing new treatments for heart failure: focus on the heart. Circ Heart Fail. 2016;9:pii: e002727.
   Google Scholar
• Sabbah HN. Targeting mitochondrial dysfunction in the treatment of heart failure. Expert Rev Cardiovasc Ther. 2016;14:1305–1313.
   PubMed Web of Science ®Google Scholar
• Brown DA, Perry JB, Allen ME, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14:228–250.
   Web of Science ®Google Scholar
• Daubert MA, Yow E, Dunn G, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10:pii: e004389.
   Web of Science ®Google Scholar
• Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37:1296–1303.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Sabbah HN, Butler J, et al. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev. 2016;21:95–102.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail. 2013;6:563–571.
   PubMed Web of Science ®Google Scholar
• Kho C, Lee A, Hajjar RJ. Altered sarcoplasmic reticulum calcium cycling-targets for heart failure therapy. Nat Rev Cardiol. 2012;9:717–733.
   PubMed Web of Science ®Google Scholar
• del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308–2311.
   PubMed Web of Science ®Google Scholar
• Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304–313.
   PubMed Web of Science ®Google Scholar
• Nicolaou P, Hajjar RJ, Kranias EG. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol. 2009;47:365–371.
   PubMed Web of Science ®Google Scholar
• Kawashima H, Satoh H, Saorome M, et al. Protein phosphatase inhibitor-1 augments a protein kinase A- dependent increase in the Ca2+ loading of the sarcoplasmic reticulum without changing its Ca2+ release. Circ J. 2009;73:1133–1140.
   PubMed Web of Science ®Google Scholar
• Moss RL, Fitzsimons DP. Myosin light chain 2 into the mainstream of cardiac development and contractility. Circ Res. 2006;99:225–227.
   PubMed Web of Science ®Google Scholar
• Warren SA, Briggs LE, Zeng H, et al. Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation. 2012;126:2575–2588.
   PubMedGoogle Scholar
• Hammond HK, Penny WF, Traverse JH, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016;1:163–171.
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Ceccarelli E, Ruocco G, et al. Clinical impact of oral antidiabetic medications in heart failure patients. Heart Fail Rev. 2018;23:325–335.
   PubMed Web of Science ®Google Scholar
• Martens P, Mathieu C, Verbrugge FH. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med. 2017;19:23.
   PubMedGoogle Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.
   PubMed Web of Science ®Google Scholar
• Radholm K, Frgtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation 2018;137. doi:10.1161/CIRCULATIONAHA.118.034222. Epub ahead of print.
   Web of Science ®Google Scholar
• Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–772.
   PubMed Web of Science ®Google Scholar
• Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol. 2017;120(suppl):S28–S36.
   PubMedGoogle Scholar
• Lytvyn Y, Bjornstad P, Udell J, et al. Sodium glucose cotransporter-2 inhibition in heart failure potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136:1643–1658.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025–1029.
   PubMed Web of Science ®Google Scholar
• Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60:568–573.
   PubMed Web of Science ®Google Scholar
• Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017;60:395–398.
   PubMed Web of Science ®Google Scholar
• Joubert M, Jagu B, Montaigne D, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66:1030–1040.
   PubMed Web of Science ®Google Scholar
• Koyani CN, Kolesnik E, Wölkart G, et al. Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure. Biochem Pharmacol. 2017 Dec 1;145:64–80.
   PubMed Web of Science ®Google Scholar
• Dalsgaard NB, Vilsbøll T, Knop FK. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20:508–519.
   PubMed Web of Science ®Google Scholar
• Li L, Li S, Liu J, et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord. 2016 May 11;16:91.
   PubMed Web of Science ®Google Scholar
• Dick SA, Epelman S. Chronic heart failure and inflammation. Circ Res. 2016;119:159.
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7:e33438.
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113:321e327.
   Web of Science ®Google Scholar
• Roubille F, Busseuil D, Merlet N, et al. Investigational drugs targeting cardiac fibrosis. Expert Rev Cardiovasc Ther. 2014;12:111–125.
   PubMedGoogle Scholar
• Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017;8:186.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Bravo-San Pedro JM, Levine B, et al. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2017;16:487–511.
   PubMed Web of Science ®Google Scholar
• Sciarretta S, Yee D, Nagarajan N, et al. Trehalose-induced activation of autophagy improves cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2018;71:1999–2010.
   PubMed Web of Science ®Google Scholar
• Manzano L, Escobar C, Cleland JG, et al. Diagnosis of elderly patients with heart failure. Eur J Heart Fail. 2012;14:1097–1103.
   PubMed Web of Science ®Google Scholar
• Lazzarini V, Mentz RJ, Fiuzat M, et al. Heart failure in elderly patients. Eur J Heart Fail. 2013;15:717–723.
   PubMed Web of Science ®Google Scholar
• Metra M, Mentz RJ, Chiswell K, et al. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. Eur J Heart Fail. 2015;17:109–118.
   PubMed Web of Science ®Google Scholar
• Díez-Villanueva P, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol. 2016;13:115–117.
   PubMedGoogle Scholar
• Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8:13–28.
   PubMed Web of Science ®Google Scholar
• Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171:550–556.
   PubMedGoogle Scholar
• Kraai IH, Vermeulen KM, Luttik ML, et al. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail. 2013;15:1113–1121.
   PubMed Web of Science ®Google Scholar
• Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF registry). Am Heart J. 2002;143:45–55.
   PubMed Web of Science ®Google Scholar
• Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30:478–486.
   PubMed Web of Science ®Google Scholar